Category: Approval/Launch Region: North America · United States Company: Astrazeneca Lp

AstraZeneca and MSDs Lynparza gets Chinese approval for 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

AstraZeneca and MSDs Lynparza gets Chinese approval for 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
AstraZeneca and MSD

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!